Search results
Chemoradiotherapy or RT in Lower Risk Early Cervical Cancer?
Medscape· 4 days agoA study found no significant differences in survival with postoperative chemoradiotherapy vs RT...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoHOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 1 day agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
These Are The Expert-Approved Ways To Help Prevent Skin Cancer | Essence
Essence· 4 days agoBy now, we know our melanin doesn’t protect us from the sun, thanks to hyperpigmentation, premature...
Robert W. Baird Cuts Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Price Target to $2.00
ETF DAILY NEWS· 7 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price objective decreased by Robert W. Baird from $4.50 to $2.00 in a research note published on Wednesday morning, Benzinga ...
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) PT Lowered to $2.00 at Robert W. Baird
ETF DAILY NEWS· 7 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price target reduced by Robert W. Baird from $4.50 to $2.00 in a report released on Wednesday, Benzinga reports. Robert W. Baird ...
Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” by StockNews.com
ETF DAILY NEWS· 5 days agoGalectin Therapeutics (NASDAQ:GALT – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday. Separately, HC ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained
How age affects laryngeal cancer rates, treatment, and more
Medical News Today· 4 days agoLaryngeal cancer is more common in older adults than in younger people. Laryngeal cancer is much...